Akademik Veri Yönetim Sistemi
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, cilt.25, sa.1, ss.447-454, 2021 (SCI-Expanded)
OBJECTIVE: Multiple sclerosis (MS) is a demyelinating, chronic, and progressive autoimmune disease of the central nervous system that causes the loss of axons and grey matter, and has a high prevalence in young female patients. Fingolimod is an oral treatment agent that acts by blocking the passage of the T lymphocytes responsible for the pathogenesis of MS from lymphoid tissue into the peripheral blood. We aimed to research the effects of menstrual cycles on leukocytes and lymphocyte levels in RRMS (relapsing-remitting MS) patients who received fingolimod treatment.